Immunogen (NASDAQ: IMGN) May call option implied volatility is at 120, June is at 77; compared to its 52-week range of 62 to 156 into announcing positive data from the FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in patients with folate receptor alpha (FRalpha)-positive ovarian cancer. Results from the cohort assessing mirvetuximab in combination with Avastin in patients with platinum-resistant disease will be presented at the 2018 American Society of Clinical Oncology, or ASCO, Annual Meeting.